GOLDEN, Colo.--(BUSINESS WIRE)--Vitro Diagnostics, Inc. (OTCBB: VODG), dba Vitro Biopharma, announced approval of its preclinical diabetes study protocol. This approval allows the Company to test its stem cell-derived human beta islets for effectiveness in reversing Type I diabetes in well-established experimental models of the disease. Positive results from such studies could further support various commercial applications of the Company’s stem cell-derived islets that are presently being developed for distribution to select non-therapeutic markets.
